RxDoctor Payments Data

Danya Godoy-Hung, MD

Pain Medicine · St. Petersburg, FLNPI 1619920493

Payments from drug & device makers

$4,760in general payments, 2019–2025

Across 129 payments — averaging $36.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Relievant Medsystems, Inc.$1K
  • Abbott$737
  • Saluda Medical Americas, Inc.$401
  • Boston Scientific$356
  • SPR Therapeutics, Inc$334
  • Nevro Corp.$238
  • plus $1K from 15 others

What the payments were for

  • Travel & lodging$76916%
  • Food & beverage$3,99184%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,760 in reported general payments places this provider in the 60th percentile of 596 pain medicine providers in Florida.

See all pain medicine providers in Florida

Medicare billing

Part B allowed, 2024
$247,461
Medicare patients
296
Services billed
2,927

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Xtampza ErOxycodone Myristate30$15,410
Buprenorphine53$14,833
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen353$13,759
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen395$11,490
OxycontinOxycodone Hcl29$11,052
ButransBuprenorphine15$8,102
Oxycodone Hcl209$7,877
Fentanyl62$5,129
Tramadol Hcl ErTramadol Hcl39$2,164
Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl22$2,037
Hydromorphone Hcl98$1,772
Morphine Sulfate ErMorphine Sulfate69$1,755
Morphine Sulfate44$1,722
Pregabalin60$1,506
Tramadol Hcl135$1,302

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Collegium Pharmaceutical, Inc.Xtampza Er$177$15,41030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 596 pain medicine providers in Florida.

Other pain medicine in St. Petersburg

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →